Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice
Hologic (NASDAQ:HOLX) Misses Q4 CY2025 Revenue Estimates
– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% –
1 Healthcare Stock Worth Investigating and 2 That Underwhelm
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously...
The Ultimate Defense campaign harnesses the power of sports to encourage lifesaving screening conversations
Shareholders should contact the firm as there may be limited time to enforce your rights.
/Hologic%2C%20Inc_%20logo%20outside%20building%20by-%20Tada%20Images%20via%20Shutterstock.jpg)
Hologic is scheduled to release its first-quarter results soon, with analysts projecting single-digit growth in its bottom line figure.